Strides Pharma Science : Intimation of Board Meeting scheduled on May 25, 2023
May 19, 2023 at 01:00 am EDT
Share
May 18, 2023
The National Stock Exchange of India Limited
The BSE Limited
Exchange Plaza, Bandra-Kurla Complex,
Phiroze Jeejeebhoy Towers,
Bandra (E), Mumbai - 400 051.
Dalal Street, Mumbai - 400 001.
Scrip Code: STAR
Scrip Code: 532531
Dear Sirs,
Re: Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations
This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday, May 25, 2023, inter alia:
To consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2023; and
To consider and recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2023.
Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from April 1, 2023 and shall open after 48 hrs post declaration of financial results by the Company.
This is for your kind information and record purposes.
Strides Pharma Science Ltd. published this content on 19 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 May 2023 04:59:09 UTC.
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.